Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Cost–Effectiveness of Pembrolizumab Versus Chemotherapy as First-Line Treatment in PD-L1-Positive Advanced Non-Small-Cell Lung Cancer in the USA

7 references·1 citing·30 second hop

FromToDepth

this work references cited by second hop

References

2016Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses3,063 cited
2014Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold2,247 cited
2008What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?578 cited
2013Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data541 cited
2017Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States142 cited
2018Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US100 cited
2019Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US79 cited

Cited by

2020Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review59 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work